Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stability of thiopurine metabolites: a potential analytical bias.
de Graaf P, de Boer NK, Jharap B, Mulder CJ, van Bodegraven AA, Veldkamp AI. de Graaf P, et al. Among authors: van bodegraven aa. Clin Chem. 2008 Jan;54(1):216-8. doi: 10.1373/clinchem.2007.092676. Clin Chem. 2008. PMID: 18160731 No abstract available.
Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting.
van Asseldonk DP, Sanderson J, de Boer NK, Sparrow MP, Lémann M, Ansari A, Almer SH, Florin TH, Gearry RB, Mulder CJ, Mantzaris G, van Bodegraven AA; Thiopurine Task Force Interest Group. van Asseldonk DP, et al. Among authors: van bodegraven aa. Dig Liver Dis. 2011 Apr;43(4):270-6. doi: 10.1016/j.dld.2010.09.001. Epub 2010 Oct 8. Dig Liver Dis. 2011. PMID: 20934926 Review.
The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease.
van Asseldonk DP, Jharap B, Verheij J, den Hartog G, Westerveld DB, Becx MC, Russel MG, Engels LG, de Jong DJ, Witte BI, Mulder CJ, van Nieuwkerk CM, Bloemena E, de Boer NK, van Bodegraven AA. van Asseldonk DP, et al. Among authors: van bodegraven aa, van nieuwkerk cm. Inflamm Bowel Dis. 2016 Sep;22(9):2112-20. doi: 10.1097/MIB.0000000000000869. Inflamm Bowel Dis. 2016. PMID: 27482972
Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease.
Spekhorst LM, Imhann F, Festen EAM, van Bodegraven AA, de Boer NKH, Bouma G, Fidder HH, d'Haens G, Hoentjen F, Hommes DW, de Jong DJ, Löwenberg M, Maljaars PWJ, van der Meulen-de Jong AE, Oldenburg B, Pierik MJ, Ponsioen CY, Stokkers PC, Verspaget HW, Visschedijk MC, van der Woude CJ, Dijkstra G, Weersma RK; Parelsnoer Institute (PSI) and the Dutch Initiative on Crohn and Colitis (ICC). Spekhorst LM, et al. Among authors: van der woude cj, van bodegraven aa, van der meulen de jong ae. BMJ Open. 2017 Nov 8;7(11):e016695. doi: 10.1136/bmjopen-2017-016695. BMJ Open. 2017. PMID: 29122790 Free PMC article.
Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.
Straatmijer T, van Schaik FDM, Bodelier AGL, Visschedijk M, de Vries AC, Ponsioen CY, Pierik M, van Bodegraven AA, West RL, de Boer NKH, Srivastava N, Romkens TEH, Hoekstra J, Oldenburg B, Dijkstra G, van der Woude JC, Löwenberg M, Mujagic Z, Biemans VBC, van der Meulen-de Jong AE, Duijvestein M. Straatmijer T, et al. Among authors: van schaik fdm, van der woude jc, van bodegraven aa, van der meulen de jong ae. Aliment Pharmacol Ther. 2023 Jan;57(1):117-126. doi: 10.1111/apt.17248. Epub 2022 Oct 25. Aliment Pharmacol Ther. 2023. PMID: 36282200 Free PMC article.
273 results